ヨーロッパの神経内分泌腫瘍市場 – 業界動向と2028年までの予測

Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

ヨーロッパの神経内分泌腫瘍市場 – 業界動向と2028年までの予測

  • Pharmaceutical
  • Published Report
  • May 2021
  • Europe
  • 350 ページ
  • テーブル数: 316
  • 図の数: 48

>ヨーロッパの神経内分泌腫瘍市場、分類別(機能性腫瘍と非機能性腫瘍)、部位別(肺、膵臓、消化管(GI))、グレード別(グレード1(低グレード腫瘍)、グレード2(中グレード腫瘍、グレード3(高グレード腫瘍))、タイプ別(診断と治療)、投与経路別(経口および非経口)、エンドユーザー別(病院、専門クリニック、放射線センター、在宅医療など)、流通チャネル別(直接入札、病院薬局、小売薬局、オンライン薬局など)、国別(ドイツ、フランス、英国、ハンガリー、イタリア、スペイン、ロシア、ポーランド、トルコ、スイス、オランダ、ベルギー、オーストリア、ノルウェー、アイルランド、リトアニア、その他のヨーロッパ諸国)2028年までの業界動向と予測

欧州神経内分泌腫瘍市場

市場分析と洞察:ヨーロッパの神経内分泌腫瘍市場

神経内分泌腫瘍市場は、2021年から2028年の予測期間に市場成長を遂げると予想されています。データブリッジマーケットリサーチは、市場は2021年から2028年の予測期間に10.2%のCAGRで成長し、2028年までに11億5,385万米ドルに達すると分析しています。神経内分泌腫瘍症例の発生率の増加は、神経内分泌腫瘍市場の推進力として機能しています。

腫瘍は、健康な細胞の DNA が損傷を受けたときに発生し、細胞が制御不能な形で変化し増殖し、その結果、細胞の凝集塊を形成します。腫瘍には、癌性のものも良性のものもあります。悪性の癌性腫瘍は、早期に発見して治療しないと、増殖して体の他の部位に広がります。良性の腫瘍は増殖しますが、広がることはありません。良性の腫瘍は通常、低侵襲手術を使用して、大きな害を及ぼすことなく除去できます。

神経内分泌腫瘍の検出に関する技術の進歩は、神経内分泌腫瘍市場の成長を促進すると期待されています。バイオマーカーと希少疾病用医薬品に対する多額の資本投資と低い費用便益比は、神経内分泌腫瘍市場の成長に対する抑制要因です。技術の進歩による治療法の出現と治療の開発は、神経内分泌腫瘍市場の成長にとって絶好の機会をもたらしています。神経内分泌腫瘍薬の開発に対する政府の厳格な規制は、神経内分泌腫瘍市場の成長に対する課題となっています。

神経内分泌腫瘍市場レポートでは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点から見た機会の詳細が提供されます。分析と神経内分泌腫瘍市場のシナリオを理解するには、アナリスト概要について Data Bridge Market Research にお問い合わせください。当社のチームが、希望する目標を達成するための収益影響ソリューションの作成をお手伝いします。  

欧州神経内分泌腫瘍市場

神経内分泌腫瘍の市場範囲と市場規模

神経内分泌腫瘍市場は、分類、部位、グレード、タイプ、投与経路、エンドユーザー、流通チャネルに基づいてセグメント化されています。セグメント間の成長は、ニッチな成長分野と市場へのアプローチ戦略を分析し、コアアプリケーション領域とターゲット市場の違いを決定するのに役立ちます。

  • 分類に基づいて、神経内分泌腫瘍市場は機能的ネットと非機能的ネットに分割されます。2021年には、識別と診断の容易さと、非機能的ネットを除去するための新しい診断方法の使用により、非機能的ネットセグメントが神経内分泌腫瘍市場を支配しています。
  • 神経内分泌腫瘍市場は、部位別に膵臓、消化管(GI)に区分されています。2021年には、胃がんの罹患率の増加と強力な製品パイプラインの存在により、神経内分泌腫瘍市場では消化管(GI)セグメントが優勢となり、市場を支配すると予測されています。
  • 神経内分泌腫瘍市場は、グレードに基づいてグレード1(低グレード腫瘍)、グレード2(中グレード腫瘍)、グレード3(高グレード腫瘍)に分類されます。2021年には、グレード2(中グレード腫瘍)セグメントが神経内分泌腫瘍市場を支配しており、これは治療によって容易に治癒できるためであり、グレード2(中グレード腫瘍)症例の増加が市場を支配すると予測されています。
  • タイプに基づいて、神経内分泌腫瘍市場は診断と治療に分かれています。2021年には、膵臓癌の発生率の増加と市場での自動化されたポイントオブケア診断の採用の増加により、診断セグメントが神経内分泌腫瘍市場を支配すると予想されます。
  • 投与経路に基づいて、神経内分泌腫瘍市場は経口と非経口に分類されます。2021年には、経口剤の入手可能性、患者のコンプライアンスの向上、吸収の容易さにより、経口セグメントが神経内分泌腫瘍市場を支配すると予想されます。
  • エンドユーザーに基づいて、神経内分泌腫瘍市場は、病院、専門クリニック、放射線センター、在宅医療などに分割されています。2021年には、医療政策が利用可能になり、神経内分泌腫瘍を検出するための診断機器が利用可能になったため、病院セグメントが神経内分泌腫瘍市場を支配すると予想されます。
  • 流通チャネルに基づいて、神経内分泌腫瘍市場は、直接入札、病院薬局、小売薬局、オンライン薬局などに分類されます。 2021年には、市場におけるサプライヤーの増加により、直接入札セグメントが神経内分泌腫瘍市場を支配すると予想されます。

神経内分泌腫瘍市場の国別分析

神経内分泌腫瘍市場は分析されており、市場規模の情報は、上記の国、分類、場所、グレード、タイプ、投与経路、エンドユーザー、流通チャネル別に提供されています。

ヨーロッパの神経内分泌腫瘍市場レポートで取り上げられている国は、ドイツ、フランス、イギリス、ハンガリー、イタリア、スペイン、ロシア、ポーランド、トルコ、スイス、オランダ、ベルギー、オーストリア、ノルウェー、アイルランド、リトアニア、その他のヨーロッパ諸国です。

神経内分泌腫瘍の症例の増加、標的療法の必要性の高まり、可処分所得の増加により、ドイツはヨーロッパの神経内分泌腫瘍市場で優位に立っています。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、グローバル ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、販売チャネルの影響も考慮されます。  

政府の取り組みの増加により、神経内分泌腫瘍市場に新たな機会が生まれています 

神経内分泌腫瘍市場では、神経内分泌腫瘍の販売を伴う特定の産業における各国の成長、神経内分泌腫瘍の進歩の影響、神経内分泌腫瘍市場への支援を伴う規制シナリオの変化に関する詳細な市場分析も提供されます。データは、2011年から2019年までの履歴期間について利用可能です。

競争環境と神経内分泌腫瘍の市場シェア分析

神経内分泌腫瘍市場の競争状況は、競合他社ごとに詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と広さ、アプリケーションの優位性、技術ライフライン曲線などがあります。提供されている上記のデータ ポイントは、神経内分泌腫瘍市場に関連する会社の焦点にのみ関連しています。

神経内分泌腫瘍市場レポートで取り上げられている企業は、F. Hoffmann-La Roche Ltd、Bristol-Myers Squibb Company、Viatris Inc.、Thermo Fisher Scientific Inc.、Novartis AG、Regeneron Pharmaceuticals, Inc.、Sun Pharmaceutical Industries Ltd.、Teva Pharmaceutical Industries Ltd.、Eli Lilly and Company、LUPIN、Exact Sciences Corporation、Pfizer Inc.、Ipsen Pharma、Advanced Accelerator Applications (Novartis AG の子会社)、Merck Sharp & Dohme Corp. (Merck & Co., Inc. の子会社)、Bionano Genomics、Illumina, Inc.、GlaxoSmithKline plc、Hutchison China MediTech Limited など、国内外の企業です。DBMR のアナリストは、競争力を理解し、各競合他社の競合分析を個別に提供します。

神経内分泌腫瘍の研究に資本投資する市場プレーヤーによる戦略的取り組みは、デング熱とその治療の間のギャップを埋めています。

例えば、

  • 2020年8月、F.ホフマン・ラ・ロシュ社は、欧州委員会が進行性非小細胞肺がんを患う成人および12歳の小児の治療薬ロズリートレクの販売承認を優先的に承認したことを発表しました。この承認は、第2相臨床試験STARTRK-2の累積分析に基づいています。同社が承認を取得したことにより、研究協力の増加、患者のタイムリーな治療、収益の増加が見込まれます。市場ではプラス成長が見込まれます。

市場プレーヤーによるコラボレーション、ジョイントベンチャー、その他の戦略により、神経内分泌腫瘍市場における企業市場が強化され、組織が神経内分泌腫瘍治療製品の提供を改善するメリットももたらされます。

 


SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

目次

  1. introduction
    1. OBJECTIVES OF THE STUDY
    2. MARKET DEFINITION
    3. OVERVIEW of THE EUROPE Neuroendocrine tumors market
    4. Currency and pricing
    5. LIMITATIONs
    6. MARKETS COVERED
  2. EUROPE Neuroendocrine tumors market: SEGMENTATION
    1. MARKETS COVERED
    2. geographical scope
    3. years considered for the study
    4. DBMR TRIPOD DATA VALIDATION MODEL
    5. primary interviews with key opinion leaders
    6. MULTIVARIATE MODELLING
    7. classification LIFELINE CURVE
    8. DBMR MARKET POSITION GRID
    9. vendor share analysis
    10. MARKET end user COVERAGE GRID
    11. secondary sourcEs
    12. assumptions
  3. EXECUTIVE SUMMARY
  4. premium insights
  5. Pipeline analysis
  6. Pricing Analysis
  7. EUROPE NEUROENDOCRINE TUMORS MARKET: REGULATIONS
    1. REGULATORY PROCEDURE IN THE U.S.
    2. REGULATORY PROCEDURE IN CANADA
    3. REGULATORY PROCEDURE IN EUROPE
    4. REGULATORY PROCEDURE IN CHINA
    5. REGULATORY PROCEDURE IN MIDDLE EAST AND AFRICA
  8. COMPARITIVE ANALYSIS BETWEEN MONOCLONAL AND POLYCLONAL ANTIBODY
    1. MONOCLONAL ANTIBODY
    2. POLYCLONAL ANTIBODY
  9. Market Overview
    1. drivers
      1. Increased incidence of neuroendocrine tumor cases
      2. Technological advanceMENT for THE detection of neuroendocrine tumors
      3. Growth in the Number of Private Diagnostic Centers and Treatment Providers
      4. Presence of targeted treatment options
      5. Favorable reimbursement policies
    2. RESTRAINTS
      1. High Capital Investments & Low Benefit-Cost Ratio for biomarkers and orphan drugs
      2. Lack of awareness among the population
      3. Unmet needs and access to medical resources in several regions
      4. High cost of Diagnosis
    3. opportunities
      1. Increased Government initiatives
      2. Emerging therapies & development in treatment
      3. Rising collaborations among the market players
    4. challenges
      1. Side effects associated with treatments
      2. Stringent government regulations for THE development OF neuroendocrine tumor drugs
  10. Impact of COVID 19 on Europe Neuroendocrine tumors market
    1. Price Impact
    2. Impact of Demand
    3. Impact on supply chain:
    4. Strategic Decisions:
    5. CONCLUSION:
  11. Europe neuroendocrine tumors market, BY Classification
    1. overview
    2. non-functional net
    3. Funtional NET
  12. Europe neuroendocrine tumors market, BY site
    1. overview
    2. gastrointestinal tract (GI)
    3. lungs
    4. pancreas
  13. Europe neuroendocrine tumors market, BY GRADE
    1. overview
    2. Grade 2 (Intermediate-Grade Tumor)
    3. grade 3 (high-grade tumor)
    4. grade 1( low-grade tumor)
  14. Europe neuroendocrine tumors market, BY type
    1. overview
    2. DIAGNOSIS
      1. Blood Test
      2. imaging test
        1. CTSCAN
        2. MRI
        3. OTHERS
      3. biopsy
      4. Urine test
      5. Others
    3. treatment
      1. somatostatin analogs
        1. OCTREOTIDE
        2. LANREOTIDE
      2. TARGETED THERAPY
        1. EVEROLIMUS
        2. SUNITINIB
        3. OTHERS
      3. RADIATION THERAPY
        1. EXTERNAL-BEAM RADIATION
        2. INTERNAL-BEAM RADIATION
      4. surgery
        1. CHOLECYSTECTOMY
        2. OTHERS
      5. LIVER-DIRECTED TREATMENT
        1. RADIO FREQUENCY ABLATION (RFA)
        2. HEPATIC ARTERY EMBOLIZATION
        3. RADIOEMBOLIZATION
      6. Peptide Receptor Radionuclide Therapy (PRRT)/ Lutathera
  15. Europe neuroendocrine tumors market, BY ROUTE OF ADMINISTRATION
    1. overview
    2. oral
      1. tablets
      2. pills
      3. others
    3. parenteral
      1. subcutaneous
      2. intramuscular
      3. others
  16. Europe neuroendocrine tumors market, BY End User
    1. overview
    2. Hospitals
    3. speciality clinics
    4. radiation centers
    5. home healthcare
    6. others
  17. Europe neuroendocrine tumors market, BY Distribution Channel
    1. overview
    2. direct tender
    3. hospital pharmacy
    4. retail sales
    5. online pharmacy
    6. others
  18. EUROPE Neuroendocrine tumors market, by Geography
    1. EUROPE
      1. germany
      2. france
      3. U.K.
      4. ITALY
      5. Russia
      6. spain
      7. SWITZERLAND
      8. NETHERLANds
      9. TURKEY
      10. IRELAND
      11. POLAND
      12. AUSTRIA
      13. NORWAY
      14. HUNGARY
      15. LITHUANIA
      16. REST OF EUROPE
  19. Europe Neuroendocrine tumors market: COMPANY landscape
    1. company share analysis: Europe
  20. SWOT
  21. company profiles
    1. F. HOFFMANN-LA ROCHE LTD
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    2. BRISTOL-MYERS SQUIBB COMPANY
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    3. VIATRIS INC.
      1. COMPANY SNAPSHOT
      2. Company share analysis
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    4. THERMO FISHER SCIENTIFIC INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    5. NOVARTIS AG
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    6. REGENERON PHARMACEUTICALS, INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    7. ADVANCED ACCELERATOR APPLICATIONS (A SUBSIDIARY OF NOVARTIS AG)
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    8. BIONANO GENOMICS
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    9. BIOSYNTHEMA INC.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    10. CALLISTOPHARMA
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    11. ELI LILLY AND COMPANY
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    12. EXACT SCIENCES CORPORATION
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    13. GLAXOSMITHKLINE PLC
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    14. HUTCHISON CHINA MEDITECH LIMITED
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    15. IPSEN PHARMA
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    16. ILLUMINA, INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    17. LUPIN
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    18. MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    19. PFIZER INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    20. SUN PHARMACEUTICAL INDUSTRIES LTD.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    21. TEVA PHARMACEUTICAL INDUSTRIES LTD.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
  22. questionnaire
  23. related reports

表のリスト

TABLE 1 Europe Neuroendocrine tumors market, Pipeline Analysis

TABLE 2 Sales Data of oncology market for 2019/2020

TABLE 3 Europe Neuroendocrine tumors market, By Classification 2019-2028(USD Million)

TABLE 4 Europe Non-Functional NET in Neuroendocrine tumors market, By Classification 2019-2027 (USD Million)

TABLE 5 Europe Functional NET in Neuroendocrine tumors market, By Classification 2019-2027 (USD Million)

TABLE 6 Europe Neuroendocrine tumors market, By Site 2019-2028 (USD Million)

TABLE 7 Europe Gastrointestinal Tract (GI) in Neuroendocrine tumors market, By Site 2019-2028 (USD Million)

TABLE 8 Europe Lungs in Neuroendocrine tumors market, By Site 2019-2028 (USD Million)

TABLE 9 Europe Pancreas Neuroendocrine tumors market, By Site 2019-2028 (USD Million)

TABLE 10 Europe Neuroendocrine tumors market, By Grade 2019-2028 (USD Million)

TABLE 11 Europe Grade 2 (Intermediate-Grade Tumor) in Neuroendocrine tumors market, By Grade 2019-2028 (USD Million)

TABLE 12 Europe Grade 3 (High-Grade Tumor) in Neuroendocrine tumors market, By Grade 2019-2028 (USD Million)

TABLE 13 Europe Neuroendocrine tumors market, By grade 2019-2028 (USD Million)

TABLE 14 Europe Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 15 Europe Diagnosis in Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 16 Europe Diagnosis in Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 17 Europe Imaging Test in Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 18 Europe Treatment Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 19 Europe Treatment in Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 20 Europe somatostatin analogs in Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 21 Europe Targeted Therapy in Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 22 Europe Radiation Therapy in Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 23 Europe surgery in Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 24 Europe liver-directed treatment in Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 25 Europe Neuroendocrine tumors market, By Route of Administration, 2019-2028 (USD Million)

TABLE 26 Europe Oral in Neuroendocrine tumors market, By Route of Administration, 2019-2028 (USD Million)

TABLE 27 Europe Oral in Neuroendocrine tumors market, By Route of Administration, 2019-2028 (USD Million)

TABLE 28 Europe Parenteral in Neuroendocrine tumors market, By Route of Administration, 2019-2028 (USD Million)

TABLE 29 Europe Parenteral in Neuroendocrine tumors market, By Route of Administration, 2019-2028 (USD Million)

TABLE 30 Europe Neuroendocrine tumors market, By End User, 2019-2028 (USD Million)

TABLE 31 Europe Hospitals in Neuroendocrine tumors market, By End User, 2019-2028 (USD Million)

TABLE 32 Europe Speciality Clinics in Neuroendocrine tumors market, By End User, 2019-2028 (USD Million)

TABLE 33 Europe Radiation Centers in Neuroendocrine tumors market, By End User, 2019-2028 (USD Million)

TABLE 34 Europe Others in radiotherapy market, By Region, 2018-2027 (USD Million)

TABLE 35 Europe Others in Neuroendocrine tumors market, By End User, 2019-2028 (USD Million)

TABLE 36 Europe Neuroendocrine tumors market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 37 Europe Direct Tender in Neuroendocrine tumors market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 38 Europe Hospital Pharmacy in Neuroendocrine tumors market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 39 Europe Retail Sales in Neuroendocrine tumors market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 40 Europe Online Pharmacy in Neuroendocrine tumors market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 41 Europe Others in Neuroendocrine tumors market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 42 EUROPE Neuroendocrine tumors market, By Country, 2019-2028 (USD Million)

TABLE 43 EUROPEneuroendocrine tumors market, By classification, 2021-2028 (USD MILLION )

TABLE 44 Europeneuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 45 EUROPEneuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 46 EUROPEneuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 47 EUROPEdiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 48 Europeimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 49 EUROPEtreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 50 EUROPEsomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 51 EUROPEtargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 52 EUROPEradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 53 EUROPEsurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 54 EUROPEliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 55 EUROPEneuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 56 EUROPEoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 57 EUROPEparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 58 EUROPEneuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 59 EUROPE neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 60 GERMANY neuroendocrine tumors market, By classification, 2021-2028 (USD MILLION )

TABLE 61 Germany neuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 62 GERMANY neuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 63 GERMANYneuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 64 GERMANYdiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 65 GERMANY imaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 66 GERMANY treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 67 GERMANY somatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 68 GERMANY targeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 69 GERMANY radiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 70 GERMANY surgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 71 GERMANYliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 72 GERMANYneuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 73 GERMANYoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 74 GERMANYparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 75 GERMANYneuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 76 GERMANY neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 77 FRANCE neuroendocrine tumors market, By classification, 2021-2028 (USD MILLION )

TABLE 78 France neuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 79 FRANCE neuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 80 FRANCE neuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 81 France diagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 82 France imaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 83 FRANCEtreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 84 FRANCEsomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 85 FRANCEtargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 86 FRANCEradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 87 FRANCEsurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 88 FRANCEliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 89 FRANCEneuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 90 FRANCEoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 91 FRANCEparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 92 FRANCEneuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 93 FRANCE neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 94 U.K. neuroendocrine tumors market, By classification, 2021-2028 (USD MILLION )

TABLE 95 U.K. neuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 96 U.K. neuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 97 U.K. neuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 98 U.K. diagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 99 U.K. imaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 100 U.K.treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 101 U.K.somatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 102 U.K.targeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 103 U.K.radiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 104 U.K.surgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 105 U.K.liver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 106 U.K.neuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 107 U.K.oral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 108 U.K.parenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 109 U.K.neuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 110 U.K. neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 111 ITALYneuroendocrine tumors market, By classification, 2021-2028 (USD MILLION )

TABLE 112 ITALYneuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 113 ITALYneuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 114 ITALYneuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 115 ITALYdiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 116 ITALYimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 117 ITALYtreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 118 ITALYsomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 119 ITALYtargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 120 ITALYradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 121 ITALYsurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 122 ITALYliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 123 ITALYneuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 124 ITALYoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 125 ITALYparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 126 ITALYneuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 127 ITALY neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 128 RUSSIA neuroendocrine tumors market, By classification, 2021-2028 (USD MILLION )

TABLE 129 RUSSIAneuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 130 RUSSIAneuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 131 RUSSIAneuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 132 RUSSIAdiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 133 RUSSIAimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 134 RUSSIAtreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 135 RUSSIAsomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 136 RUSSIAtargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 137 RUSSIAradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 138 RUSSIAsurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 139 RUSSIAliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 140 RUSSIAneuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 141 RUSSIAoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 142 RUSSIAparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 143 RUSSIAneuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 144 RUSSIA neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 145 SPAIN neuroendocrine tumors market, By classification, 2021-2028 (USD MILLION )

TABLE 146 SPAIN NEUROENDOCRINE TUMORS MARKET, By site, 2021-2028 (USD Million)

TABLE 147 SPAIN NEUROENDOCRINE TUMORS MARKET, By grade, 2021-2028 (USD Million)

TABLE 148 SPAIN NEUROENDOCRINE TUMORS MARKET, By Type, 2021-2028 (USD Million)

TABLE 149 SPAINdiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 150 SPAINimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 151 SPAINtreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 152 SPAINsomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 153 SPAINtargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 154 SPAINradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 155 SPAINsurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 156 SPAINliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 157 SPAIN NEUROENDOCRINE TUMORS MARKET, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 158 SPAINoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 159 SPAINparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 160 SPAIN NEUROENDOCRINE TUMORS MARKET, By end user, 2021-2028 (USD Million)

TABLE 161 SPAIN neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 162 SWITZERLAND neuroendocrine tumors market, By classification, 2021-2028 (USD MILLION )

TABLE 163 SWITZERLAND neuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 164 SWITZERLANDneuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 165 SWITZERLANDneuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 166 SWITZERLANDdiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 167 SWITZERLANDimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 168 SWITZERLANDtreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 169 SWITZERLANDsomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 170 SWITZERLANDtargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 171 SWITZERLANDradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 172 SWITZERLANDsurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 173 SWITZERLANDliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 174 SWITZERLANDneuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 175 SWITZERLANDoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 176 SWITZERLANDparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 177 SWITZERLANDneuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 178 SWITZERLAND neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 179 NETHERLANDs neuroendocrine tumors market, By classification, 2021-2028 (USD MILLION )

TABLE 180 NETHERLANDs neuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 181 NETHERLANDs neuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 182 NETHERLANDs neuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 183 NETHERLANDs diagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 184 NETHERLANDs imaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 185 NETHERLANDs treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 186 NETHERLANDs somatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 187 NETHERLANDs targeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 188 NETHERLANDs radiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 189 NETHERLANDs surgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 190 NETHERLANDs liver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 191 NETHERLANDs neuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 192 NETHERLANDs oral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 193 NETHERLANDs parenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 194 NETHERLANDs neuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 195 NETHERLANDs neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 196 Turkey neuroendocrine tumors market, By classification, 2021-2028 (USD MILLION)

TABLE 197 Turkey neuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 198 Turkey neuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 199 Turkey neuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 200 Turkey diagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 201 Turkey imaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 202 Turkey treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 203 Turkey somatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 204 Turkey targeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 205 Turkey radiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 206 Turkey surgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 207 Turkey liver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 208 Turkey neuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 209 Turkey oral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 210 Turkey parenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 211 Turkey neuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 212 Turkey neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 213 Irelandneuroendocrine tumors market, By classification, 2021-2028 (USD MILLION)

TABLE 214 Irelandneuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 215 Irelandneuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 216 Irelandneuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 217 Irelanddiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 218 Irelandimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 219 Irelandtreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 220 Irelandsomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 221 Irelandtargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 222 Irelandradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 223 Irelandsurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 224 Irelandliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 225 Irelandneuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 226 Irelandoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 227 Irelandparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 228 Irelandneuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 229 Ireland neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 230 Polandneuroendocrine tumors market, By classification, 2021-2028 (USD MILLION)

TABLE 231 Polandneuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 232 Polandneuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 233 Polandneuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 234 Polanddiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 235 Polandimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 236 Polandtreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 237 Polandsomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 238 Polandtargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 239 Polandradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 240 Polandsurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 241 Polandliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 242 Polandneuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 243 Polandoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 244 Polandparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 245 Polandneuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 246 Poland neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 247 Austrianeuroendocrine tumors market, By classification, 2021-2028 (USD MILLION)

TABLE 248 Austrianeuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 249 Austrianeuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 250 Austrianeuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 251 Austriadiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 252 Austriaimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 253 Austriatreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 254 Austriasomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 255 Austriatargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 256 Austriaradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 257 Austriasurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 258 Austrialiver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 259 Austrianeuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 260 Austriaoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 261 Austriaparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 262 Austrianeuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 263 Austria neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 264 Norwayneuroendocrine tumors market, By classification, 2021-2028 (USD MILLION)

TABLE 265 Norwayneuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 266 Norwayneuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 267 Norwayneuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 268 Norwaydiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 269 Norwayimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 270 Norwaytreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 271 Norwaysomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 272 Norwaytargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 273 Norwayradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 274 Norwaysurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 275 Norwayliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 276 Norwayneuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 277 Norwayoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 278 Norwayparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 279 Norwayneuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 280 Norway neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 281 Hungaryneuroendocrine tumors market, By classification, 2021-2028 (USD MILLION)

TABLE 282 Hungaryneuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 283 Hungaryneuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 284 Hungaryneuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 285 Hungarydiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 286 Hungaryimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 287 Hungarytreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 288 Hungarysomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 289 Hungarytargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 290 Hungaryradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 291 Hungarysurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 292 Hungaryliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 293 Hungaryneuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 294 Hungaryoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 295 Hungaryparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 296 Hungaryneuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 297 Hungary neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 298 Lithuanianeuroendocrine tumors market, By classification, 2021-2028 (USD MILLION)

TABLE 299 Lithuanianeuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 300 Lithuanianeuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 301 Lithuanianeuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 302 Lithuaniadiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 303 Lithuaniaimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 304 Lithuaniatreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 305 Lithuaniasomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 306 Lithuaniatargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 307 Lithuaniaradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 308 Lithuaniasurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 309 Lithuanialiver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 310 Lithuanianeuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 311 Lithuaniaoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 312 Lithuaniaparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 313 Lithuanianeuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 314 Lithuania neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 315 REST OF EUROPE Neuroendocrine tumors market, By classification 2019-2028 (USD Million)

TABLE 316 Lithuanianeuroendocrine tumors market, By classification, 2021-2028 (USD MILLION)

図表一覧

FIGURE 1 EUROPE Neuroendocrine tumors market: segmentation

FIGURE 2 EUROPE Neuroendocrine tumors market: data triangulation

FIGURE 3 EUROPE NEUROENDOCRINE TUMORS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE Neuroendocrine tumors market: Europe VS REGIONAL ANALYSIS

FIGURE 5 EUROPE Neuroendocrine tumors market: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE Neuroendocrine tumors market: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE Neuroendocrine tumors market: DBMR MARKET POSITION GRID

FIGURE 8 Europe neuroendocrine tumors market: vendor share analysis

FIGURE 9 Europe neuroendocrine tumors market: MARKET end user COVERAGE GRID

FIGURE 10 EUROPE Neuroendocrine tumors market: SEGMENTATION

FIGURE 11 increased awareness of neuroendocrine tumors cases is expected to drive the EUROPE Neuroendocrine tumors market in the forecast period of 2021 to 2028

FIGURE 12 non-funtional net segment is expected to account for the largest share of the Europe Neuroendocrine tumors market in 2021 & 2028

FIGURE 13 FIVE YEAR SURVIVAL RATE OF PANCREATIC NEUROENDOCRINE TUMOR BETWEEN 2010- 2016

FIGURE 14 INCIDENCE OF NEO-ENDOCRINE NEOPLASM IN CHINA, EUROPE AND U.S.

FIGURE 15 Europe neuroendocrine tumors market: BY classification, 2020

FIGURE 16 EUROPE neuroendocrine tumors market, BY classification, 2020-2028 (USD MILLION)

FIGURE 17 EUROPE neuroendocrine tumors market: BY classification, CAGR (2021-2028)

FIGURE 18 EUROPE neuroendocrine tumors market: BY classification, LIFELINE CURVE

FIGURE 19 Europe neuroendocrine tumors market: BY site, 2020

FIGURE 20 EUROPE neuroendocrine tumors market, BY site, 2020-2028 (USD MILLION)

FIGURE 21 EUROPE neuroendocrine tumors market: BY site, CAGR (2021-2028)

FIGURE 22 EUROPE neuroendocrine tumors market: BY site, LIFELINE CURVE

FIGURE 23 Europe neuroendocrine tumors market: BY grade, 2020

FIGURE 24 EUROPE neuroendocrine tumors market, BY grade, 2020-2028 (USD MILLION)

FIGURE 25 EUROPE neuroendocrine tumors market: BY grade, CAGR (2021-2028)

FIGURE 26 EUROPE neuroendocrine tumors market: BY grade, LIFELINE CURVE

FIGURE 27 Europe neuroendocrine tumors market: BY type, 2020

FIGURE 28 EUROPE neuroendocrine tumors market, BY type, 2020-2028 (USD MILLION)

FIGURE 29 EUROPE neuroendocrine tumors market: BY type, CAGR (2021-2028)

FIGURE 30 EUROPE neuroendocrine tumors market: BY type, LIFELINE CURVE

FIGURE 31 Europe neuroendocrine tumors market: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 32 EUROPE neuroendocrine tumors market, BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)

FIGURE 33 EUROPE neuroendocrine tumors market: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)

FIGURE 34 EUROPE neuroendocrine tumors market: BY ROUTE OF ADMINSTRATION, LIFELINE CURVE

FIGURE 35 Europe neuroendocrine tumors market: BY end user, 2020

FIGURE 36 EUROPE neuroendocrine tumors market, BY end user, 2020-2028 (USD MILLION)

FIGURE 37 EUROPE neuroendocrine tumors market: BY end user, CAGR (2021-2028)

FIGURE 38 EUROPE neuroendocrine tumors market: BY end user, LIFELINE CURVE

FIGURE 39 Europe neuroendocrine tumors market: BY distribution channel, 2020

FIGURE 40 EUROPE neuroendocrine tumors market, BY distribution channel, 2020-2028 (USD MILLION)

FIGURE 41 EUROPE neuroendocrine tumors market: BY distribution channel, CAGR (2021-2028)

FIGURE 42 EUROPE neuroendocrine tumors market: BY distribution channel, LIFELINE CURVE

FIGURE 43 EUROPE neuroendocrine tumors market: SNAPSHOT (2020)

FIGURE 44 EUROPE neuroendocrine tumors market: BY COUNTRY (2020)

FIGURE 45 EUROPE neuroendocrine tumors market: BY COUNTRY (2021 & 2028)

FIGURE 46 EUROPE neuroendocrine tumors market: BY COUNTRY (2021 & 2028)

FIGURE 47 EUROPE neuroendocrine tumors market: BY classification (2021-2028)

FIGURE 48 Europe neuroendocrine tumors market: company share 2020 (%)

詳細情報を見る Right Arrow

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。